Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer?
Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer?
复制标题
DOI：
10.3389/fonc.2021.594917
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Monteiro MC
中科院分区：
文献类型：
--
作者：
Ferreira RG;Narvaez LEM;Espíndola KMM;Rosario ACRS;Lima WGN;Monteiro MC
胰腺癌是一种侵袭性、破坏性的疾病，因为它具有侵袭性、快速进展以及对手术、药物、化学疗法和放射疗法的抗性。该疾病从PanIN病变发展而来，经过不同阶段。在这些病变中经常观察到KRAS突变，伴随着PTEN的失活、PI 3 K/AKT通路的过度活化和伴随考克斯-2过表达的慢性炎症。尼美舒利是一种选择性考克斯-2抑制剂，在胰腺肿瘤细胞中显示出抗癌作用。这种药物通过增加PTEN表达水平并抑制增殖和凋亡起作用。然而，需要通过固体脂质纳米颗粒对其进行包封来改善尼美舒利，以克服与药物的肝毒性和生物利用度相关的问题。
Pancreatic cancer is an aggressive, devastating disease due to its invasiveness, rapid progression, and resistance to surgical, pharmacological, chemotherapy, and radiotherapy treatments. The disease develops from PanINs lesions that progress through different stages. KRAS mutations are frequently observed in these lesions, accompanied by inactivation of PTEN, hyperactivation of the PI3K/AKT pathway, and chronic inflammation with overexpression of COX-2. Nimesulide is a selective COX-2 inhibitor that has shown anticancer effects in neoplastic pancreatic cells. This drug works by increasing the levels of PTEN expression and inhibiting proliferation and apoptosis. However, there is a need to improve nimesulide through its encapsulation by solid lipid nanoparticles to overcome problems related to the hepatotoxicity and bioavailability of the drug.
登录
查看更多内容
影响因子：
3.4
作者：
Campos, Joana R.;Fernandes, Ana R.;Souto, Eliana B.
通讯作者：
Souto, Eliana B.
影响因子：
4.7
作者：
Alfieri R;Giovannetti E;Bonelli M;Cavazzoni A
通讯作者：
Cavazzoni A
影响因子：
1.7
作者：
Ebada, Sherif S.;El-Neketi, Mona;Proksch, Peter
通讯作者：
Proksch, Peter
DOI：
10.1016/s0731-7085(98)00172-1
发表时间：
1998-10-01
影响因子：
3.4
作者：
Carini, M;Aldini, G;Facino, RM
通讯作者：
Facino, RM
影响因子：
3.4
作者：
Donati, Monia;Conforti, Anita;Leone, Roberto
通讯作者：
Leone, Roberto